Nissi Strategy & Marketing’s principal consultant, Levi Kirwin has been contracted to provide services to Cytophenix to support marketing and market access activities. An expert in navigating health-system pathways and unlocking adoption at scale, his deep expertise in positioning and market access in key target markets strengthens Cytophenix’s commercial strategy.
Levi has more than 20 years’ experience in clinical diagnostics and medical technology including roles as Director of Marketing, Clinical Diagnostics at Alexion Pharmaceuticals, Head of Marketing at Accelerate Diagnostics and Marketing Manager at Beckman Coulter, as well as various life science industry sales roles.
He will deliver materials and strategic advice that will accelerate the commercial development of FloCAST™ – the next generation rapid antimicrobial susceptibility test (AST) platform.
About Cytophenix
Cytophenix is a medical technology company developing an AI-powered, cloud-hosted platform, FloCAST™ which is designed to help clinicians administer the right antibiotics in hours instead of days, saving lives and helping to combat antimicrobial resistance globally. The company has its origins in the labs of The Harry Perkins Institute of Medical Research and the University of Western Australia, and is based at the Centre for Entrepreneurial Research and Innovation (CERI) in Perth. Cytophenix closed a successful pre-seed round in Q3 2025 raising $1.32 M and has partnered with Three Springs Technology for development of its proprietary software. Find out more and connect here: https://cytophenix.com/
The need for rapid AST
For patients with serious infections, like the bloodstream infections that cause sepsis, getting the right antibiotic is a time critical emergency. Every hour without the right antibiotic results in ~ 9% increased risk of death. With timely AST results, doctors can have certainty about the best antibiotic to use, and this helps them protect antibiotics from misuse and overuse, which helps address the growing global threat of antimicrobial resistance (AMR), as well as freeing up hospital beds.